How can polycythemia vera be distinguished from secondary polycythemia?

Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by an increase in red blood cell mass, commonly resulting from a mutation in the JAK2 gene that drives erythropoiesis independent of erythropoietin (EPO) levels. One key distinguishing feature of PV is the level of erythropoietin in circulation.

In polycythemia vera, the erythropoietin levels are typically low because the increased red blood cell production is driven by the neoplastic process rather than by low oxygen levels or other stimuli that would normally increase EPO secretion. This leads to a normal or suppressed level of erythropoietin, contrasting with secondary polycythemia, where elevated erythropoietin levels are commonly seen due to external factors, such as chronic hypoxia or tumors producing EPO.

Additionally, individuals with polycythemia vera generally have normal oxygen saturation levels as their condition is not due to hypoxemia. In contrast, secondary polycythemia often occurs in the context of conditions that lead to decreased oxygen availability (e.g., chronic lung diseases, sleep apnea, or living at high altitude).

Thus, the statement that suggests polycythem